[go: up one dir, main page]

MA48728B1 - Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate - Google Patents

Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate

Info

Publication number
MA48728B1
MA48728B1 MA48728A MA48728A MA48728B1 MA 48728 B1 MA48728 B1 MA 48728B1 MA 48728 A MA48728 A MA 48728A MA 48728 A MA48728 A MA 48728A MA 48728 B1 MA48728 B1 MA 48728B1
Authority
MA
Morocco
Prior art keywords
niraparib
prednisone
prostate cancer
abiraterone acetate
treatment
Prior art date
Application number
MA48728A
Other languages
English (en)
Other versions
MA48728A (fr
Inventor
Margaret K Yu
Linda Anne Snyder
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA48728(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA48728A publication Critical patent/MA48728A/fr
Publication of MA48728B1 publication Critical patent/MA48728B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne des méthodes et des compositions permettant de traiter le cancer de la prostate par l'administration à un patient qui en a besoin d'une quantité thérapeutiquement efficace d'un inhibiteur de parp, par exemple le niraparib ; d'une quantité thérapeutiquement efficace d'un inhibiteur de cyp17, par exemple, l'acétate d'abiratérone, et d'une quantité thérapeutiquement efficace d'un glucocorticoïde, par exemple la prednisone.
MA48728A 2017-04-13 2018-04-09 Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate MA48728B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
PCT/US2018/026661 WO2018191141A1 (fr) 2017-04-13 2018-04-09 Polythérapie contre le cancer de la prostate

Publications (2)

Publication Number Publication Date
MA48728A MA48728A (fr) 2020-04-08
MA48728B1 true MA48728B1 (fr) 2022-10-31

Family

ID=62067858

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48728A MA48728B1 (fr) 2017-04-13 2018-04-09 Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate

Country Status (33)

Country Link
US (4) US20180296574A1 (fr)
EP (3) EP4176878A1 (fr)
JP (3) JP7141408B2 (fr)
KR (1) KR20190134718A (fr)
CN (2) CN110753545A (fr)
AU (2) AU2018251594A1 (fr)
CA (1) CA3059562A1 (fr)
CL (1) CL2019002871A1 (fr)
CO (1) CO2019011591A2 (fr)
CR (1) CR20190467A (fr)
DK (1) DK3609497T3 (fr)
DO (1) DOP2019000264A (fr)
EA (1) EA201992430A1 (fr)
ES (1) ES2931052T3 (fr)
HR (1) HRP20221327T1 (fr)
HU (1) HUE060460T2 (fr)
IL (2) IL320452A (fr)
JO (1) JOP20190244A1 (fr)
LT (1) LT3609497T (fr)
MA (1) MA48728B1 (fr)
MD (1) MD3609497T2 (fr)
MX (2) MX2019012296A (fr)
MY (1) MY209010A (fr)
NI (1) NI201900105A (fr)
PE (1) PE20200444A1 (fr)
PH (1) PH12019502317A1 (fr)
PL (1) PL3609497T3 (fr)
PT (1) PT3609497T (fr)
RS (1) RS63832B1 (fr)
SG (1) SG11201909552VA (fr)
SM (1) SMT202200467T1 (fr)
UA (1) UA129514C2 (fr)
WO (1) WO2018191141A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3490560T1 (sl) 2016-07-29 2025-04-30 Janssen Pharmaceutica, N.V. Niraparib za uporabo pri metodi zdravljenja raka prostate
WO2020139339A1 (fr) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Inhibiteurs de la signalisation de l'ezh2 et du récepteur des androgènes en tant qu'outils pour le ciblage du cancer de la prostate
CN116785301A (zh) 2019-09-26 2023-09-22 湖南慧泽生物医药科技有限公司 含醋酸阿比特龙的药物组合物及其制备方法和应用
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
AU2021267146A1 (en) * 2020-05-08 2023-01-19 Janssen Pharmaceutica Nv Treatments of prostate cancer with combinations of abiraterone acetate and niraparib
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
WO2023109758A1 (fr) 2021-12-15 2023-06-22 Hunan Huize Biopharma S&T Co., Ltd Composition contenant de l'acétate d'abiratérone et son application
KR20240170958A (ko) * 2022-04-07 2024-12-05 아스트라제네카 아베 암 치료를 위한 병용 요법
WO2024203348A1 (fr) * 2023-03-31 2024-10-03 ソニーグループ株式会社 Procédé d'analyse de tumeurs, système d'analyse de tumeurs et procédé de génération de données d'analyse de tumeurs
CN121443291A (zh) * 2023-08-02 2026-01-30 詹森药业有限公司 尼拉帕尼和阿比特龙组合用于治疗转移性去势抵抗性前列腺癌

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
KR20180003636A (ko) * 2006-08-25 2018-01-09 코우가 바이오테크놀로지, 인크. 암을 치료하기 위한 방법 및 조성물
EP2109608B1 (fr) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Indazoles à substitution amide utilisés comme inhibiteurs de la poly(adp-ribose)polymérase (parp)
WO2009087381A1 (fr) 2008-01-08 2009-07-16 Merck Sharp & Dohme Ltd Sels pharmaceutiquement acceptables de 2-{4-[(35)-pipéridin-3-yl]phényl)-2h-indazole-7-carboxamide
WO2012009475A1 (fr) * 2010-07-14 2012-01-19 Oregon Health & Science University Méthodes de traitement du cancer par inhibition de la déméthylase 1 spécifique de la lysine
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (fr) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Composés cycliques substitués et leurs procédés d'utilisation

Also Published As

Publication number Publication date
DOP2019000264A (es) 2020-07-15
UA129514C2 (uk) 2025-05-21
CN110753545A (zh) 2020-02-04
PL3609497T3 (pl) 2023-01-23
EP4176878A1 (fr) 2023-05-10
BR112019021466A2 (pt) 2020-05-12
IL320452A (en) 2025-06-01
CO2019011591A2 (es) 2020-02-28
MD3609497T2 (ro) 2023-03-31
HRP20221327T1 (hr) 2023-03-17
MX2023009569A (es) 2023-08-22
MY209010A (en) 2025-06-16
PH12019502317A1 (en) 2020-07-06
EP3609497A1 (fr) 2020-02-19
NI201900105A (es) 2020-03-11
JP2022141881A (ja) 2022-09-29
CL2019002871A1 (es) 2019-12-27
DK3609497T3 (da) 2022-10-31
US20240398837A1 (en) 2024-12-05
JP2024023344A (ja) 2024-02-21
IL269879B2 (en) 2025-10-01
IL269879B1 (en) 2025-06-01
WO2018191141A1 (fr) 2018-10-18
EA201992430A1 (ru) 2020-02-28
AU2018251594A1 (en) 2019-10-24
PT3609497T (pt) 2023-01-23
EP3609497B1 (fr) 2022-10-12
SG11201909552VA (en) 2019-11-28
ES2931052T3 (es) 2022-12-23
CA3059562A1 (fr) 2018-10-18
JP2020516646A (ja) 2020-06-11
CR20190467A (es) 2020-03-09
PE20200444A1 (es) 2020-02-28
MA48728A (fr) 2020-04-08
KR20190134718A (ko) 2019-12-04
AU2024202346A1 (en) 2024-05-02
LT3609497T (lt) 2022-12-12
CN119235874A (zh) 2025-01-03
AU2024202346B2 (en) 2026-01-22
SMT202200467T1 (it) 2023-01-13
JP7407880B2 (ja) 2024-01-04
EP4176879A1 (fr) 2023-05-10
US20240245710A1 (en) 2024-07-25
JOP20190244A1 (ar) 2019-10-13
MX2019012296A (es) 2019-11-28
JP7141408B2 (ja) 2022-09-22
IL269879A (fr) 2019-11-28
US20180296574A1 (en) 2018-10-18
HUE060460T2 (hu) 2023-03-28
RS63832B1 (sr) 2023-01-31
US20220175801A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
MA48728B1 (fr) Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate
MA46269B1 (fr) Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
EA202091144A1 (ru) Ганаксолон для использования в лечении наследственных эпилептических заболеваний
MA38493B1 (fr) Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
EP3908601A4 (fr) Procédés et compositions pour le traitement du cancer
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
SA523440622B1 (ar) أجسام مضادة
EA202191170A1 (ru) Комбинированная терапия для лечения гематологических заболеваний
EP3723733A4 (fr) Méthodes et compositions pour le traitement du cancer utilisant des exosomes associés à l'édition génique
EP3347010A4 (fr) Synthèse et composition d'agents thérapeutiques photodynamiques pour le traitement ciblé du cancer
EP4138869A4 (fr) Compositions et méthodes comprenant clostridium butrycum pour le traitement du cancer
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
EP4149547A4 (fr) Compositions et méthodes pour le traitement du cancer
MX2017011237A (es) Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides.
BR112019006329A2 (pt) métodos de tratamento de câncer do trato biliar
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MA50341A (fr) Méthodes de traitement du cancer de la prostate par administration d'acétate d'abiratérone et de prednisone avec une thérapie par privation androgénique
BR112022022590A2 (pt) Formulações farmacêuticas de acetato de abiraterona e niraparibe
EP3987032A4 (fr) Méthodes et compositions permettant le traitement du cancer
MY204443A (en) Pyridopyrimidinone derivatives for use as axl inhibitors
MA55888B1 (fr) Hétéroarylaminopyrimidine amides inhibiteurs d'autophagie et leurs procédés d'utilisation
WO2024220955A3 (fr) Combinaison d'induction de ferroptose avec des agents ciblés pour une thérapie anticancéreuse